This study reports a new mechanism of protection that is mediated by influenza hemagglutinin-11 stalk reactive antibodies: inhibition of neuraminidase activity by steric hindrance, blocking access 12 of neuraminidase to sialic acids when it is abutted next to hemagglutinin on whole virions.
The appreciated mechanism of protection by HA-stalk antibodies is to inhibit HA stalk 17 reconfiguration, blocking viral fusion and entry. This study shows that HA stalk-reactive 18 antibodies also inhibit neuraminidase (NA) enzymatic activity, prohibiting viral egress. NA 19 inhibition (NI) is evident for an attached substrate but not for unattached small molecule cleavage 20 of sialic acid. This suggests that the antibodies inhibit NA enzymatic activity through steric 21 hindrance, thus limiting NA access to sialic acids when adjacent to HA on whole virions. 22 Consistently, F(ab')2 fragments that occupy reduced area without loss of avidity or disrupted 23 HA/NA interactions show significantly reduced NI activity. Notably, HA stalk binding antibodies 24 lacking NI activity were unable to neutralize viral infection via microneutralization assays. This 25 work suggests that NI activity is an important component of HA-stalk antibody mediated 26 protection. 27 28 Introduction: 29 Influenza is an acute respiratory illness that causes epidemics and pandemics in the human 30 population, causing up to 640,000 deaths annually worldwide (Iuliano et al., 2017) . The influenza 31 virus particle contains two major surface glycoproteins, hemagglutinin (HA) and neuraminidase 32 (NA). HA is a tetramer protein that contains a globular head and a stalk domain. The head domain 33 mediates binding to host cellular receptor sialic acids, while the stalk domain fuses the virus and 34 host cell membranes to allow the introduction of the influenza virus genes. The NA protein is 35 essential for cleaving terminal sialic acid residues present on host glycoproteins ( Figure 1A) , 36 allowing the ready dispersal of the newly generated virus (Matrosovich et al., 2004; Palese and 37 Compans, 1976) . 38 Antibodies are a major means of protection from influenza virus infections. Antibody-mediated 39 immunity is the basis of current vaccines and most efforts for improving immunity to influenza. 40 Influenza virus vaccinations induce antibodies that predominantly target the immunodominant 41 globular head of influenza HA that blocks viral attachment to prevent infection (Corti et al., 2010; 42 Wrammert et al., 2011) . However, immunity to the HA-head domain is highly susceptible to 43 influenza antigenic drift, or viral mutation, introducing novel amino acids and glycosylation sites 44 that allow the virus to evade existing immunity. The stalk is a more conserved domain, allowing 45 antibodies that target this region to neutralize a wide spectrum of influenza virus subtypes (Corti 46 et al., 2011; Ekiert et al., 2009; Neu et al., 2016; Okuno et al., 1993) . The current appreciated 47 mechanism of protection by HA stalk-reactive antibodies (Abs) is to lock the hemagglutinin trimer 48 in a pre-fusion conformation, preventing pH triggered conformational changes upon viral uptake 49 into endocytic compartments. This conformational change exposes the fusion peptide that 50 mediates fusion of the viral membrane to the host cell membrane and subsequent introduction of 51 the viral genome (Wu and Wilson, 2018) . Because of the highly conserved epitopes within the 52 HA-stalk domain, induction of antibodies targeting this domain are the basis of several universal 53 influenza vaccine concepts and ongoing clinical trials. Herein, we describe an additional 54 mechanism of protection that is mediated by HA-stalk binding antibodies: the inhibition of NA 55 activity through steric hindrance blocking access to HA-bound sialic acid. 56 We used a panel of well-characterized HA stalk-reactive mAbs to explore how the mAbs interfere 57 with NA enzymatic activity as measured by enzyme linked lectin assay (ELLA) or the NA-STAR 58 assay. ELLA uses sialated glycoprotein fetuin that is immobilized as a substrate to measure NI. 59 This immobilized substrate will identify antibodies that inhibit either directly by binding close to 60 the enzymatic active site or that sterically inhibits NA from abutting close enough to HA to cleave 61 the sialic acid (Couzens et al., 2014) . Conversely, the NA-STAR assay uses a small, soluble 62 chemiluminescent substrate, and so more explicitly distinguishes antibodies that directly inhibit the enzymatic activity of NA by binding close to the enzymatic site (Chen et al., 2018; Nguyen et 64 al., 2010) . Herein, we show that HA stalk-reactive mAbs inhibit the enzymatic activation of 65 influenza A viruses by ELLA but not in NA-STAR assays, supporting a steric-inhibition model. 66 Moreover, we detected reduced NI activity for the F(ab')2 fragments from the stalk-reactive mAbs 67 compared to the same whole antibodies, providing direct evidence that anti-HA stalk antibodies 68 are sterically limiting NA access to sialic acids. The NI activity of HA-stalk binding but not NA-69 binding antibodies is disrupted by dissociating HA and NA from virions, further supporting steric-70 hindrance based mechanism of NI. Notably, only antibodies against the HA stalk with NI activity, 71 including 2 with high affinity binding, were able to mediate microneutralization. These findings 72 suggest that an important component of protection by anti-HA stalk reactive antibodies is via 73 steric-inhibition of NI activity. 229-2C06 against H3N2 influenza). The mechanism of action of these antibodies is likely through 81 steric inhibition of NA from accessing sialic acid molecules bound by HA ( Figure 1C , left). 82 Similarly, antibodies to epitopes on the outside periphery of the globular head of HA that do not 83 inhibit hemagglutination, and so do not bind the HA receptor-binding domain, can nonetheless 84 mediate protection by inhibiting viral egress similar to NI (Dreyfus et al., 2012) . Thus, we 85 hypothesized that antibodies to the stalk region of HA, which will occupy space on the side of the 86 molecule, could similarly mediate NI activity, compounding the mechanism of protection 87 mediated to include both inhibition of fusion and inhibition of egress. As expected (Kosik and 88 Yewdell, 2017), antibodies binding the HA-head region of H1N1 and H3N2 influenza virus strains 89 robustly inhibit NA activity by ELLA ( Figure 1B , EM-4C04 against H1N1 influenza and 3-50008-90 2A06 against H3N2 influenza) because HA cannot bind the sialic acid on fetuin, and so NA is not 91 in enough proximity for enzymatic activity ( Figure 1C , right). To determine if HA-stalk antibodies 92 elicit NI activity, we tested the well-characterized mAb 045-2B06 (Henry Dunand et al., 2015) 93 that binds the HA-stalk regions of group 1 and 2 influenza A HA molecules and mAb CR9114 that 94 binds the HA-stalk of both A and B influenza strain HAs (Dreyfus et al., 2012) . Both of these 95 antibodies neutralize influenza in vitro and protect mice in vivo upon lethal challenge with 96 influenza and can competitively inhibit the binding of the other (Henry Dunand et al., 2015) , 97 demonstrating that they bind similar protective HA-stalk epitopes. We find that both 045-2B06 98 and CR9114 provide NI activity against both A/California/7/2009 (H1N1) and 99 A/Switzerland/9715293/2013 (H3N2) by ELLA assay ( Figure 1D ). The likely mechanism for this 100 inhibition is steric hindrance in which the antibodies block access of NA to the sialic acids mound 101 by HA ( Figure 1E ). Conversely, neither 045-2B06 nor CR9114 had NI-activity to cleave the small, 102 unattached substrate in the NA-STAR assay ( Figure 1F ), suggesting a mechanism of steric 103 hindrance (compare Figures 1E versus 1G ). Our results demonstrate that human antibodies reactive 104 to the HA-stalk inhibit the enzymatic activity of NA protein on H1N1 and H3N2 influenza virus 105 particles.
107
Stalk-reactive mAbs interfere with NA activity by steric hindrance 108 Because the antibodies inhibited NI activity on the attached substrate of the ELLA assay but not 109 on the free substrate of the NA-STAR assay, as depicted in Figures 1D and 1F , it appears the 110 mechanism of inhibition is likely steric hindrance of NA access to the sialic acid when bound by 111 HA. To investigate this possibility directly, we generated F(ab')2 molecules from the 045-2B06 112 and CR9114 mAbs to reduce the size of the molecules, and thus the degree of steric hindrance, 113 without affecting the avidity of binding. The F(ab')2 concentration of protein were also increased 114 to ensure equivalent binding of the F(ab')2 molecules with that of the mAbs (Figure 2A and 2B). 115 Comparison via the ELLA assay showed that indeed the F(ab')2 molecules had significantly 116 reduced NI activity in comparison to the whole mAbs against both H1N1 and H3N2 influenza 117 viruses ( Figure 2C ). Thus, while not completely allowing access of NA to the sialic acid, the 118 smaller antibody fragments allowed increased NA access to the substrate ( Figure 2D ), supporting 119 a steric hindrance model of NI by HA-stalk binding antibodies. As a final verification that 120 antibodies to the HA-stalk were inhibiting NA through steric hindrance, we dissociated the HA 121 and NA molecules from the virions, thus allowing NA to access the sialic acid substrates 122 completely independently of HA, regardless of the presence of antibody. For this analysis we 123 performed the ELLA assay in the presence of 1% of Triton X-100 to disrupt the viral envelope 124 lipid bilayer, releasing HA and NA similarly to seasonal split influenza virus vaccine production 125 (Gross et al., 1981) . The detergent treatment completely abrogated NI activity of all the HA-stalk-126 reactive and HA-head-reactive mAbs against both H1N1 and H3N2 virus strains, further 127 supporting the steric hindrance model for NI activity ( Figure 3A and 3B) . However, the NA-128 reactive antibodies were able to inhibit NI activity, demonstrating integrity of the assay after 129 detergent treatment. In total, these various results demonstrate that in addition to the well-130 appreciated mechanism of action disrupting viral entry, antibodies to the HA-stalk region also 131 inhibit the access of NA to sialic acid by steric hindrance and thus reduce viral egress. Figure 4B and 4D). Notably, none of these antibodies had NI activity using the NA-STAR assay 147 ( Figure 4E -H), suggesting that as with CR9114 and 045-2B06, they all inhibit NI via steric 148 interference of NA to sialic acid. Importantly, after testing the panel of mAbs by 149 microneutralization (MN) assay, we noted that only those antibodies that have NI activity were 150 able neutralize viral infection in vitro ( Figure 5A and 5B). While two of the antibodies that lack 151 MN capacity were low avidity, possibly explaining the lack of both MN and NI activities, the other 152 two were of equal avidity to the set of HA stalk binding antibodies that did inhibit NI and neutralize 153 ( Figure 5C ). The lack of NI and MN activity of two of the HA-stalk binding antibodies that have 154 high avidity suggests that the epitope is bound in an atypical fashion. Thus we considered if these 155 antibodies were of the stereo-typical variety with restricted variable gene repertoires, biased for 156 VH1-69 and VH1-18 immunoglobulin heavy chain gene usage. Notably, while most of the NI+ 157 antibodies appear to be stereotypical ( Figure 6A ), none of the NI-negative anti-HA stalk antibodies 158 used the most typical anti-HA stalk VH gene, VH1-69 ( Figure 6B ). Also, one of the high avidity 159 but NI-negative antibodies used VH3-23, which is indeed atypical, while the other high avidity 160 NI-negative antibody was encoded by VH1-18, which is a common stalk-related gene that is highly 161 similar to VH1-69. There were no other features of the immunoglobulin gene repertoire that were 162 distinct between NI-positive and NI-negative antibodies ( Figure 6C-6F) . These studies 163 demonstrate that while the majority of HA-stalk reactive antibodies inhibit NA activity a subset 164 do not and the capacity for NI appears to be important for potency.
166
Discussion: 167 The development of a "one-shot" universal influenza vaccine that will provide long-term or 168 improved immunity to influenza epidemics and pandemics is currently a major focus of the 169 biomedical community (Paules et al., 2017a; Paules et al., 2017b) . The HA stalk is an important 170 target for the ongoing design of universal influenza vaccines and for recent and ongoing clinical 171 trials because the protective epitopes in this portion of HA are highly conserved across many 172 influenza subtypes (Henry et al., 2018; Krammer et al., 2018; Wu and Wilson, 2018) . While the 173 appreciated mechanism of action of HA-stalk binding antibodies is to inhibit viral entry via 174 disrupting the HA conformational change required for viral-envelope to host cell membrane fusion, 175 there was one recent report using a microscopy-based assay suggesting the anti-HA stalk 176 antibodies also block influenza virus particle release (Yamayoshi et al., 2017) . Herein, we show 177 that antibodies to the HA-stalk region inhibit the activity of NA through steric hindrance on whole 178 virions, adding to the mechanisms of protection mediated by this broadly-reactive class of 179 antibodies, and providing a mechanism for the previously observed inhibition of viral release. 180 It is notable that not all antibodies binding the HA-stalk region can inhibit NI activity, although 181 for the collection of anti-stalk antibodies tested for this study, NI activity correlated perfectly with 182 MN activity. Thus, NI activity is in the least an important correlate of neutralization-capacity, or 183 at most a critical component of the activity of anti-HA stalk binding antibodies. In future studies, 184 it will be important to distinguish the relative contributions of inhibiting viral entry versus viral 185 egress for HA-stalk reactive antibodies in protection. 186 A second interesting observation that should be evaluated is that there is a potential correlation 187 between the capacity for NI activity and the type of HA-stalk antibody elicited in that none of the 188 NI-negative antibodies binding the HA stalk were encoded by the stereotypical VH1-69 gene. A 189 more substantial evaluation of many anti-stalk antibodies for various properties and structural 190 studies to evaluate the particular contact residues and angle of binding for stalk-binding antibodies 191 that are NI will provide insight into this issue. Identifying stereotypical features for anti-HA stalk 192 antibodies with NI activity could inform on universal influenza vaccine design by, for example, 193 providing an impetus to develop germline boosting prime-boost strategies to elicit a particular 194 class of anti-HA stalk antibodies preferentially. 195 In conclusion, this study identifies NI inhibition as a new and additional mechanism of action for 196 the important class of anti-influenza antibodies that bind highly-conserved epitopes on the HA Acknowledgments: 308 We thank Nai-Ying Zheng for purifying influenza viruses and experimental assistance. This 
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